Abstract: The present invention addresses the problem of providing a means for making highly sensitive and stable measurements possible using electrochemical measurement methods. This problem is resolved by providing: a labeling substance represented by general formula (1) and used to label a substrate; a measurement substrate that is formed by being labeled using the labeling substance; a method of measuring using electrochemical measurement methods that use the measurement substrate; and a reagent kit that includes as components the labeling substance and/or the measurement substrate. (In general formula (1), R1 is either H or an alkyl group (CmH2m+1), m is an integer of 1-4, R2 is an alkyl group (CnH2n+1), and n is an integer of 1-4.

Abstract: There is provided a package wherein a pharmaceutical composition containing a saccharide-degrading enzyme is contained in a container, whereby reduction in titer caused by a low amount of enzyme is suppressed. A package comprising a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a saccharide-degrading enzyme as an active ingredient, and the container contains the pharmaceutical composition, the inner surface of the container comprising at least one material selected from the group consisting of fine ceramics, silicone resins and fluorine resins.

Abstract: There are provided a pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/?g as an active ingredient, and containing the saccharide-degrading enzyme in an amount of not less than 2 ?g and not more than 8 ?g.

Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.

Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. Specifically provided is a composition for treating joint diseases that obtains higher efficacy than prior preparations by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is targeted at patients with human joint diseases who have a BMI of 25 kg/m2 or higher.

Abstract: The present invention relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, and a pharmaceutically acceptable carrier, and which can be stored at room temperature. The present invention also relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, sorbitol, and a pharmaceutical acceptable carrier.

Abstract: Provided is an agent for proving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.

Abstract: Provided is an agent for proving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.

Abstract: A main object of the present disclosure is to provide a drug storage container enabling simple and reliable preparation of a mixed solution containing a drug and an auxiliary agent, a closing member that is for use in the drug storage container and configured to detachably retain a solid preparation containing a drug or an auxiliary agent, a method for manufacture of the drug storage container, a microbial contaminant test method using the drug storage container, and a solid preparation for preparing a buffer solution.

Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

Abstract: A therapeutic agent containing, as an effective component, a glycolytic enzyme which is different from a deficient protein of a patient with lysosomal storage disease as a subject and/or a glycolytic enzyme which does not have a mannose 6-phosphate moiety or a mannose moiety.

Abstract: The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.

Abstract: The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.

Abstract: Provided is a compound obtained by conjugating a tertiary amine compound or imine compound, which is useful as a drug, with a polymer, in which a structure D+ having a quaternary ammonium salt or iminium salt formed from a tertiary amine compound or imine compound D and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R1)(R2)OC(O)ANHC(?O)—.

Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.

Abstract: Provided is a preparation to be applied to an ophthalmic device comprising a cinnamic acid derivative, the application of which to the ophthalmic device can ameliorate symptoms on the ocular surface or prevent damage on the ocular surface.

Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

Abstract: The invention provides a diamine crosslinking agent for acidic polysaccharides consisting of a diamine compound having a primary amino group at both terminals and an ester or thioester bond in the molecule, wherein the number of atom in the linear chain between at least one of the amino groups and the carbonyl carbon in the ester or thioester is 1 to 5; in particular, a diamine crosslinking agent for acidic polysaccharides which is represented by the general formula (I) below: [the symbols in the formula are as described in the specification]; a crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between the amino groups in the diamine crosslinking agent and carboxyl groups in an acidic polysaccharide; and a medical material including the crosslinked product.

Abstract: An object of the present invention is to provide means for correctly measuring zygomycota. The present inventors have found that conventionally difficult zygomycota measurement can be performed through subjecting an untreated specimen to an acid treatment. The present invention provides a method for measuring zygomycota, the method including measuring zygomycota in a specimen that was subjected to an acid treatment; an agent for preparing a specimen for measurement of zygomycota; a method for preparing a specimen for measurement of zygomycota; and a reagent kit for measuring zygomycota.